The core therapeutic domains of this medicine generally involve support for cardiovascular and general circulatory health, specifically regarding its application in heart and blood vessel conditions.

The medicine is applied across domains where additional symptomatic support is needed for symptoms that create noticeable physiological strain and arise from impaired blood flow. It is commonly used to help with symptom clusters related to chronic coronary heart disease, peripheral arterial disease, and arterial hypertension. Furthermore, it may be part of symptomatic management in specialized contexts, including supporting symptom clusters associated with preeclampsia and relevant for easing symptoms related to systemic imbalance, in situations where patients experience elevated ammonia levels.

“By providing support that helps ease the overall symptom burden, the medicine assists with maintaining functional stability during periods of heightened symptoms.”

This use is relevant when supportive symptom management is appropriate for symptoms that interfere with daily functioning, contributing to improved day-to-day comfort and helping patients cope more steadily with physically limiting episodes.

---

Quick Fact: Support for Circulatory Discomfort

Property	Description
Primary Focus	Symptoms of reduced vascular perfusion, functional capacity limitation
Contexts of Use	Chronic heart disease, peripheral artery pain (claudication), specialized maternal health support
Patient Benefit	Contributes to improved tolerance for physical exertion and may assist in easing discomfort
Clinical Goal	Applied in clinical settings that involve acute and chronic vascular scenarios

Regulatory References

1. NIH MedlinePlus Overview of L-Arginine Uses

The eligibility for using Тивортин (L-Arginine Aspartate) is determined by official regulatory documents, which establish specific populations that are prohibited from use and those that require special caution.

Contraindicated Populations

The medicine is formally contraindicated and must not be used by the following groups:

• Children and Adolescents: Individuals aged under 18 years are excluded due to insufficient data on the safety and efficacy of the medicine in the pediatric population [1.4].
• Severe Renal Impairment: Patients with severe kidney problems (renal impairment) [1.4, 1.5].
• Recent Myocardial Infarction: Individuals who have recently experienced an acute myocardial infarction [1.5].
• Hypersensitivity: Patients with known allergy to the active substance, L-Arginine Aspartate, or any of the product's components [1.4].

Conditional Use and Caution

Certain conditions require additional caution or a specific risk assessment before the medicine can be administered:

• Pregnancy: Use during pregnancy is conditional and is authorized only if the expected maternal benefit outweighs the potential risk to the fetus [1.4].
• Lactation/Breastfeeding: No data are available on the use of this medicine in nursing mothers [1.4].
• Comorbidities: Caution is required for patients with pre-existing electrolyte disturbances, non-severe renal diseases, and those with angina pectoris (chest pain) [1.4, 1.5].

Interactions with other medicines and products

Official regulatory documents describe the interaction profile of Тивортин (L-Arginine Aspartate) primarily through pharmacodynamic interactions that may result in additive physiological effects, requiring careful consideration during co-administration.

---

Documented Pharmacodynamic Interactions

Co-administration with several classes of medication may lead to reinforced effects as described in official labeling:

• Antihypertensive Medicines and Nitrates: Combining with drugs for high blood pressure, such as ACE inhibitors or ARBs, or with nitrates (e.g., Isosorbide Mononitrate), carries the potential for an additive hypotensive effect (lowering of blood pressure) due to reinforced vasodilation.
• Electrolyte Imbalance: Co-use with potassium-sparing diuretics (e.g., Amiloride, Spironolactone) presents an additive risk of hyperkalemia (elevated potassium levels). This risk is specifically noted as heightened in patients with severe kidney or liver disease.
• Blood Clotting: The concurrent administration of L-Arginine with anticoagulant or antiplatelet drugs may contribute to an increased risk of bleeding or bruising.

---

Specific Restrictions and Incompatibility

• Specific Incompatibility: The sterile solution for infusion is formally stated as incompatible with Thiopental for co-administration.
• Substance Restrictions: Some regulatory labels advise that patients should refrain from alcohol, nicotine, and psychostimulants during the period of treatment.
• Metabolic Outcome: The co-administration of Aminophylline may be associated with an increase in blood insulin levels.

L-Arginine: The Substrate for Nitric Oxide Synthesis

The active component, L-Arginine, functions as the essential substrate for the enzyme Nitric Oxide Synthase (NOS), particularly in the endothelial lining of blood vessels. By increasing the available supply of this precursor, the drug enhances the production of Nitric Oxide (NO), a critical endogenous signaling molecule. This mechanism involves the provision of substrate to overcome relative limitations and modulating the inhibitory effects of Asymmetric Dimethylarginine (ADMA).

---

Cascade for Vascular Smooth Muscle Relaxation

The newly formed Nitric Oxide rapidly diffuses to the surrounding vascular smooth muscle cells, where it activates the enzyme Soluble Guanylate Cyclase (sGC). This activation elevates the secondary messenger, cyclic Guanosine Monophosphate (cGMP), which triggers the sequence that results in relaxation (vasodilation) of the vessel walls. This physiological consequence is central to reducing Systemic Vascular Resistance and adjusts blood flow dynamics.

---

️ Support for Nitrogen Homeostasis

In addition to its vascular effects, L-Arginine is a key intermediate in the Urea Cycle, the body's primary metabolic pathway for detoxifying nitrogenous waste products like ammonia. The specific formulation as L-Arginine Aspartate leverages the metabolic role of the Aspartate component to influence this detoxification pathway. This action influences the regulation of nitrogen homeostasis in parallel with the circulatory effects.

Administration Guidelines for Тивортин

The usage of Тивортин (L-Arginine Aspartate) follows specific parameters, establishing rules for administration route, dosage, and intake conditions.

Administration scope	Detail
Route of administration	Intravenous (IV) infusion and Oral solution
Dosing schedule	Intravenous: Typically 100 mL to 250 mL of the 4.2% solution daily. Oral: Total daily dose, up to a maximum of 8 g, is taken in multiple divided uses.
Timing in relation to meals	The oral solution must be taken during meals with a sufficient quantity of water.
Special procedural conditions	The IV solution requires slow administration, typically controlled to a rate not exceeding 30 drops per minute. A reduced dose is mandatory for patients presenting with severe renal impairment.
Age-group rules	The product is generally not intended for use in patients under 18 years of age.

---

Procedural Structure

The protocol dictates a time-dependent use pattern where the intravenous administration serves as a short course, generally lasting 5 to 10 days. This route requires specialist supervision due to the necessary controlled infusion rate. Following or separate from the acute phase, the oral solution is utilized for maintenance or supportive courses, typically spanning 8 to 15 days. The oral regimen requires dividing the total dose throughout the day and ensuring intake occurs concurrently with food.

Research Evidence / Overview of studies for Тивортин (L-Arginine)

---

Evidence for Vascular and Circulatory Support

Evidence for use in Arterial Hypertension (High Blood Pressure)

The research exploring the active component's role in high blood pressure is largely based on systematic reviews and meta-analyses that combine data from numerous short-term, placebo-controlled clinical trials. These studies were used in research examining outcomes related to physiological strain, specifically focusing on measurements of systolic and diastolic blood pressure. They also monitored measurements of specific blood markers related to vascular function. Studies describe patterns in the blood pressure measurements recorded in the groups that received the active ingredient. However, researchers have noted significant statistical inconsistency (or heterogeneity) across compiled trials. The research so far primarily provides insight into short-term changes, and long-term effects are not fully established regarding sustained blood pressure management.

Evidence for use in Chronic Coronary Heart Disease

Research exploring this context involved small-scale randomized controlled trials (RCTs) and systematic reviews applied in studies examining outcomes related to functional imbalance. Studies monitored functional outcomes, such as walking distance during tests, and evaluated measurements of small blood vessel function in the heart. Findings were mixed regarding the measurements recorded for certain vascular function markers. Data show patterns related to physical discomfort were often based on trials with modest sample sizes. Research has explored its use alongside existing medications for coronary disease, and the resulting data have shown inconsistency across trials.

---

Evidence in Specialized Health Contexts

Evidence for use in Pregnancy-Related Hypertension (Preeclampsia)

This specialized area has been the subject of randomized controlled clinical trials and meta-analyses. The research was applied in studies examining patient-reported experiences in women who were at high risk for developing preeclampsia or who had existing gestational hypertension. Studies tracked the number of cases of preeclampsia development in the study groups and monitored outcomes including measurements of maternal blood pressure and specific neonatal health metrics at birth. Sample sizes were modest in many trials, and follow-up durations were limited to the pregnancy and immediate post-delivery period.

---

The Broader Research Landscape

What is Still Uncertain about the Evidence

The primary uncertainty stems from mixed findings across various indications, with some studies reporting observed patterns while others observe no significant changes in key outcomes or biomarkers. Evidence quality varies across studies, with many trials being small, and sample sizes were modest, contributing to lower certainty in the findings. The comparative evidence is lacking against many standard-of-care treatments for the long term.

Key Studies & References Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials (2011)

Common questions about Тивортин (FAQ)

Q: What is Тивортин (Tivortin) used for?

Тивортин (Tivortin) is a medication that contains the active ingredient L-arginine aspartate. It is typically prescribed to improve endothelial function (the health of the lining of blood vessels) and enhance microcirculation (blood flow in the smallest blood vessels). It is used as part of complex therapy for a variety of conditions, including:

• Cardiovascular diseases, such as coronary artery disease or hypertension (high blood pressure).
• Atherosclerosis and its complications.
• Conditions associated with impaired blood circulation and oxygen supply to tissues (ischemia).
• Diabetic angiopathy (blood vessel damage due to diabetes).
• Conditions involving the liver and kidneys where improved microcirculation is desired.

Q: How does Тивортин (Tivortin) work?

Тивортин works due to its active component, L-arginine. L-arginine is an amino acid that serves as the primary precursor for the synthesis of nitric oxide (NO) in the body. Nitric oxide is a potent vasodilator, meaning it helps to relax and widen blood vessels. This effect leads to:

• Improved blood flow throughout the body.
• Reduced blood pressure.
• Better oxygen and nutrient delivery to various tissues and organs, including the heart and brain.

Additionally, L-arginine plays a role in the detoxification process in the liver by participating in the urea cycle, which helps remove ammonia from the body.

Q: What are the common forms of Тивортин (Tivortin)?

Тивортин is available in two main forms:

1. Solution for infusion (intravenous drip): This form is typically used in acute or severe conditions when a rapid and sustained effect is needed. It allows the active ingredient to enter the bloodstream directly.
2. Oral solution (liquid to be taken by mouth): This form is often used for maintenance therapy or less severe conditions.

The specific formulation and concentration will be determined by a healthcare provider based on the patient's condition and therapeutic needs.

Q: Can I take Тивортин (Tivortin) if I have kidney problems?

If you have pre-existing kidney impairment (renal insufficiency), you should use Тивортин with caution. The medication is processed and eliminated by the kidneys. In cases of severe renal impairment, the body may not be able to clear the medication effectively, potentially leading to accumulation.

• It is crucial to inform your doctor about any history of kidney disease or current kidney problems.
• Your doctor may need to adjust the dosage or monitor your kidney function closely while you are taking Тивортин. The benefit-risk profile should be assessed by a healthcare professional.

Q: What should I avoid while taking Тивортин (Tivortin)?

While taking Тивортин, patients should be mindful of potential interactions and conditions:

• Avoid co-administration with medications that can significantly alter potassium levels, especially potassium-sparing diuretics (certain 'water pills') and aldosterone antagonists, unless closely monitored by a doctor.
• Limit the intake of high-protein foods if you have severe liver impairment, as L-arginine is involved in the protein metabolism pathway (urea cycle).
• Alcohol consumption should be discussed with a doctor, as it can potentially affect circulation and overall health, which may be counterproductive to the treatment.
• Sildenafil (Viagra) and similar medications that also affect nitric oxide pathways should be used with caution, as combining them with Тивортин could theoretically lead to excessive lowering of blood pressure. Always consult your healthcare provider about all medications and supplements you are taking.

Q: Are there any side effects of Тивортин (Tivortin)?

As with all medications, Тивортин can cause side effects, although not everyone experiences them. Common side effects may include:

• Gastrointestinal issues like nausea, discomfort, or diarrhea.
• Allergic reactions (rarely), which can manifest as rash or itching.
• Hypotension (lowering of blood pressure), especially with rapid infusion of the intravenous solution.
• Local irritation or phlebitis (inflammation of the vein) at the injection site for the intravenous form.

If you experience any severe or persistent side effects, or signs of a serious allergic reaction (e.g., swelling of the face, difficulty breathing), you should seek immediate medical attention. Most side effects are mild and resolve on their own.

Official Storage and Disposal Instructions

The storage and disposal of Тивортин (L-Arginine Aspartate) must strictly follow the requirements detailed in the official regulatory documents to maintain product integrity and safety.

Mandatory Storage Conditions

Condition	Requirement
Temperature	Store at a temperature not exceeding 25 C (seventy-seven degrees Fahrenheit).
Protection	Must be protected from light and protected from moisture.
Packaging	Store in the original package.
Child Safety	Keep out of the sight and reach of children.

Disposal Requirements

Unused or expired product must be disposed of in accordance with local legal requirements for pharmaceutical waste. The official instructions mandate that the medicine must not be thrown into household waste or disposed of through wastewater.